| abstract |
The invention relates to the field of biotechnology, specifically to a modified oligonucleotide, directed to the human androgen receptor (AR) to inhibit the levels of androgen receptor in the cell, and can be used in medicine. The resulting modified oligonucleotide and its pharmaceutically acceptable salt are used in the composition to inhibit the levels of the androgen receptor in the cell, as well as to inhibit the proliferation or growth of cancer cells, such as prostate cancer, breast cancer, ovarian cancer, stomach cancer or bladder cancer . Due to its structure and mechanism of action, the oligonucleotide allows you to target the androgen receptor mRNA and induce antiproliferative responses in the cell. 4 n. and 16 hp f-ly, table 146, 34, etc. |